LP
MDGL icon

LMR Partners’s Madrigal Pharmaceuticals MDGL Stock Holding History

LMR Partners’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-2,000
Closed -$617K – 1545
2024
Q4 		$617K Buy
+2,000
New +$563K 0.01% 800
2024
Q3 		– Sell
-1,700
Closed -$476K – 1432
2024
Q2 		$476K Buy
1,700
+200
+13% +$47.6K ﹤0.01% 775
2024
Q1 		$401K Buy
+1,500
New +$353K ﹤0.01% 794

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

LMR Partners's MDGL Position: Q3 2025 in Review

LMR Partners sold out of Madrigal Pharmaceuticals (MDGL) in Q3 2025, closing a stake of 1,242 shares — an estimated $376K sold.

LMR Partners first reported a position in MDGL in Q2 2016 and held it in 7 quarters. The position peaked at $12M in Q4 2023. 352 funds tracked by Wall St. Rank hold MDGL as of Q3 2025.

  • LMR Partners reported no remaining Madrigal Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • LMR Partners sold 1,242 Madrigal Pharmaceuticals shares in Q3 2025, an estimated $376K.
  • LMR Partners first reported a position in Madrigal Pharmaceuticals in Q2 2016 and held it in 7 quarters.
  • LMR Partners's Madrigal Pharmaceuticals position peaked at $12M in Q4 2023.
  • 352 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q3 2025.

Based on LMR Partners's 13F filing for Q3 2025, filed 14 Nov 2025.